Cracking the Code of BIN/PCN/Group Data for Faster Benefit Verification
This article was originally published in Drug Channels. As patient access grows more complex, manufacturers need tools that reduce friction throughout the care journey. One valuable but frequently overlooked dataset is known as BIN/PCN/Group (BPG) data, which refers to a trio of identifiers used in pharmacy claims processing. Unlocking the power of BPG data can […]
New Treatments, Diagnostic Tests and Access Barriers in NSCLC
The oncology market is growing rapidly, driven by advancements in diagnostic technology, new biomarker testing, and a wealth of targeted therapies. The non-small cell lung cancer (NSCLC) space is especially crowded, which should be good news for the 226,000 patients diagnosed with this disease each year. Despite the new developments in NSCLC treatment, however, many […]
How to Mitigate Payer Pushback on Fast-Tracked Therapies
For pharma manufacturers, securing expedited approval for a drug in development is typically seen as a win, which will result in faster patient access as well as faster revenue recognition. However, the realities of market access mean that drugs approved by expedited pathways—most notably, the accelerated approval pathway—may face a much more difficult path to […]
How PBMs Are Reshaping Biosimilar Market Access
As biosimilars continue to redefine the specialty drug landscape, payers and their associated pharmacy benefit managers (PBMs) are executing new strategies to capture a larger share of revenue. PBMs are partnering with manufacturers to co-develop and commercialize their own private-labeled biosimilar products. This coordinated approach provides value to both parties, as it enables them to […]
Apples to Apples: Stelara Biosimilars and the Fight for Market Share
Over the next five years, 88 biologics—including several blockbuster agents like Eliquis, Keytruda, Opdivo, and Darzalex—are facing a loss of exclusivity, representing an estimated market of more than $100 billion. After the fierce competition between Humira (adalimumab) biosimilars, manufacturers are keeping a close eye on adoption dynamics for biosimilars of Johnson & Johnson’s autoimmune drug, […]
Contextualizing Market Access: How Advisors Bridge the Knowledge Gap
For pharma companies, securing favorable coverage for a new asset is far more complicated than it used to be. Indications are more competitive, and the market is full of specialized niche therapies for smaller patient populations. While market access data has never been easy to parse, we’ve seen an evolution in the amount and type […]
The Impact of Expedited Approvals on Payer Coverage
To speed patient access to potentially life-saving therapies, the FDA established expedited approval pathways for selected drugs that fill unmet needs or treat serious conditions. For patients in need, these pathways serve an essential purpose. But many payers and providers are concerned that expedited pathways do not require sufficient safety and efficacy data. Their concerns […]
Patient Access Barriers in 2025 and Beyond
The landscape of patient access has become increasingly complex, intensified by evolving channel dynamics, greater biosimilar investment, and legislative reform. As payers evolve their utilization management tactics, manufacturers must also become more sophisticated in their access strategies. To explore these topics, MMIT and The Dedham Group conducted the second annual State of Patient Access Survey […]
GLP-1s and the Evolving Sleep Apnea Landscape
Obstructive sleep apnea (OSA) is a prevalent yet underdiagnosed condition affecting millions worldwide. People with OSA are subject to sudden drops in blood oxygenation levels that can lead to severe cardiovascular, metabolic, and cognitive consequences if the condition remains untreated. Traditionally, OSA has been managed through personal appliances that apply continuous positive airway pressure (CPAP). […]
Promoting Your Brand: Six Steps for Success
Months and months of market access planning occur long before a new therapy is approved. Once that therapy is finally on the market, pharma companies must then turn their attention to the art of effective brand promotion. While the first step is identifying the right prescribing physicians, how manufacturers engage with these HCPs is equally […]